References: 1. Data on file, Amgen; [Analysis of AACR Genie v12]. 2. Tan AC, et al. J Clin Oncol. 2022;40:611-625. 3. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019;39:531-542.
4. Mullard A, et al. Nat Rev Drug Discov. 2019;18:887-891.
5. Hess LM, et al. JTO Clin Res Rep. 2022;3:100336.
6. American Cancer Society. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed April 1, 2023. 7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.2.2023.
© National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 17, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 8. Thein KZ, et al. JCO Precis Oncol. 2022;6:e2100547. 9. Skoulidis F, et al. Nat Rev Cancer. 2019;19:495-509. 10. Spira A, et al. Lung Cancer. 2021;159:1-9. 11. Nadler E, et al. Presented at: The American Society of Clinical Oncology Annual Meeting; June 2021; Virtual Congress.